多纳尼马布:首次批准
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
多纳尼马布是一种粉样β向抗体,目前已在美国批准用于早期阿尔茨海默病. 这标志着治疗轻度认知障碍和痴呆阶段的重要里程碑.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病是一种进展性神经退行性疾病,其特点是粉样β斑块的积累.
- 目前的治疗方法可以缓解症状,但不能阻止疾病的进展.
- 多纳尼马布代表了一种新的治疗方法,针对阿尔茨海默病的潜在病理.
研究的目的:
- 总结一下donanemab的关键发展里程碑.
- 突出监管途径导致美国批准早期阿尔茨海默病.
主要方法:
- 对donanemab的临床前和临床发展数据的审查.
- 对监管提交和审批流程的分析.
主要成果:
- 针对聚合性粉样β的抗体Donanemab已经经历了广泛的开发.
- 该药物已获得美国批准用于早期症状阿尔茨海默病患者.
- 这项批准意味着针对特定患者群体的潜在新治疗选择.
结论:
- 多纳尼马布的开发之旅突出了阿尔茨海默氏症治疗方法的进步.
- 批准为管理早期阿尔茨海默病的治疗提供了新的途径.
- 进一步的研究和现实世界的数据对于理解donanemab的长期影响至关重要.
更多相关视频
09:39Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
Published on: September 17, 2019
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
相关概念视频
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Drug Products: Biologics, Biosimilars and Interchangeables
FDA Approved Drugs: Changes to Approved Drugs
